Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
88.38+2.26 (+2.62%)
At close: 04:00PM EST
87.05 -1.33 (-1.50%)
After hours: 07:45PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close86.12
Open86.79
Bid88.44 x 800
Ask90.00 x 900
Day's Range85.87 - 89.04
52 Week Range71.59 - 92.57
Volume1,030,681
Avg. Volume1,433,700
Market Cap16.226B
Beta (5Y Monthly)0.49
PE Ratio (TTM)2,455.00
EPS (TTM)0.04
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est115.89
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
75% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BMRN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioMarin Pharmaceutical Inc.
    Analyst Report: BioMarin Pharmaceutical Inc.BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.
    Rating
    Fair Value
    Economic Moat
    20 days agoMorningstar
View more
Advertisement
Advertisement